

1000
US PATIENTS



autologous cultured
chondrocytes
on porcine
collagen membrane

Use of MACI (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) in the United States

Preliminary Experience

JUMP TO PUBLICATION >

James L. Carey, MD, MPH, Ann E. Remmers, PhD, and David C. Flanigan, MD

Investigation performed at the Perelman School of Medicine,
University of Pennsylvania, Philadelphia, Pennsylvania, USA

The Orthopaedic Journal of Sports Medicine [Internet]. 2020 August;8(8):1-7.
Available from: <https://doi.org/10.1177/2325967120941816>

Indication: MACI[®] (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement.

Limitations of Use: Effectiveness of MACI in joints other than the knee has not been established. Safety and effectiveness of MACI in patients over the age of 55 years have not been established.

For more information, please see [full Indication and Important Safety Information](#) and [full Prescribing Information](#).

MACI.COM





autologous cultured
chondrocytes
on porcine
collagen membrane

MACI experience of 1000 US patients: patient demographics and cartilage defect characteristics

Purpose	Study design	Methods
To describe the cartilage defects and patient characteristics for 1000 adult patients treated with MACI for knee cartilage repair in the United States.	Case series; Level of evidence, 4	Data were collected for 1000 consecutive patients treated with MACI (on 1010 knee joints) between July 1, 2017 and November 30, 2019 by 372 surgeons.

Patient demographics and cartilage defect characteristics



- The ratio of treated adult patients was evenly split between male (**49.6%**) and female (**50.4%**).
- The mean patient age was **34** (range: 17-61).

- **68.1%** of patients had a single defect treated.
- The mean treated defect size was **4.7 cm²**.
- The mean total treated lesion size, including multiple defects, was **5.8 cm²**.

Defect locations for single defect surgeries:	36.5%	patella	15.8%	lateral femoral condyle
	29.1%	medial femoral condyle	0.9%	tibia
	17.7%	trochlea		

Important Safety Information: MACI is contraindicated in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin. MACI is also contraindicated for patients with severe osteoarthritis of the knee, inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders. MACI is also not indicated for use in patients who have undergone prior knee surgery in the past 6 months, excluding surgery to procure a biopsy or a concomitant procedure to prepare the knee for a MACI implant.

For more information, please see [Indication and Important Safety Information](#) and [full Prescribing Information](#).



autologous cultured
chondrocytes
on porcine
collagen membrane

MACI experience of 1000 US patients: patient characteristics compared to the pivotal European SUMMIT trial

Concomitant procedures

At the time of cartilage biopsy acquisition, **92.4%** of patients had concomitant procedures, including:

83.7% debridement of the cartilage lesion

11.3% meniscal resection

other concomitant procedures $\leq 5\%$ of patients

At the time of MACI implantation, **13.2%** of patients had planned concomitant procedures, including:

7.8% anterior tibial tubercleplasty

5.5% reconstruction of dislocating patella

3.4% osteotomy, tibia (including high tibial osteotomy)

other concomitant procedures $\leq 2\%$ of patients

Safety and adverse events

Very few patients (26; 2.6%) experienced adverse events (AEs). The most commonly reported AE was arthralgia, reported in 8 (0.8%) patients. No events were reported in more than 1% of patients. A total of 85 AEs were reported in 26 patients with a follow-up period up to 28 months.

Conclusions for 1000 MACI patients in the United States

Patient age and mean total MACI-treated defect size in the United States are similar to the findings of the pivotal European SUMMIT (Superiority of MACI Implant Versus Microfracture Treatment) trial and other studies from outside the United States.

Treatment of multiple cartilage defects is more frequent in the United States than elsewhere (31% compared to 19%).

Important Safety Information: MACI is contraindicated in patients who are unable to follow a physician-prescribed post-surgical rehabilitation program. The safety of MACI in patients with malignancy in the area of cartilage biopsy or implant is unknown. Expansion of present malignant or dysplastic cells during the culturing process or implantation is possible.

For more information, please see [Indication and Important Safety Information](#) and [full Prescribing Information](#).

MACI.COM



autologous cultured
chondrocytes
on porcine
collagen membrane

INDICATION

MACI[®] (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement.

MACI is intended for autologous use and must only be administered to the patient for whom it was manufactured. The implantation of MACI is to be performed via an arthrotomy to the knee joint under sterile conditions.

The amount of MACI administered is dependent upon the size (surface in cm²) of the cartilage defect. The implantation membrane is trimmed by the treating surgeon to the size and shape of the defect, to ensure the damaged area is completely covered, and implanted cell-side down.

Limitations of Use

Effectiveness of MACI in joints other than the knee has not been established.

Safety and effectiveness of MACI in patients over the age of 55 years have not been established.

IMPORTANT SAFETY INFORMATION

MACI is contraindicated in patients with a known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin. MACI is also contraindicated for patients with severe osteoarthritis of the knee, inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders. MACI is also not indicated for use in patients who have undergone prior knee surgery in the past 6 months, excluding surgery to procure a biopsy or a concomitant procedure to prepare the knee for a MACI implant.

MACI is contraindicated in patients who are unable to follow a physician-prescribed post-surgical rehabilitation program.

The safety of MACI in patients with malignancy in the area of cartilage biopsy or implant is unknown. Expansion of present malignant or dysplastic cells during the culturing process or implantation is possible.

Patients undergoing procedures associated with MACI are not routinely tested for transmissible infectious diseases. A cartilage biopsy and MACI implant may carry the risk of transmitting infectious diseases to healthcare providers handling the tissue. Universal precautions should be employed when handling the biopsy samples and the MACI product.

Final sterility test results are not available at the time of shipping. In the case of positive sterility results, health care provider(s) will be contacted.

To create a favorable environment for healing, concomitant pathologies that include meniscal pathology, cruciate ligament instability and joint misalignment, must be addressed prior to or concurrent with the implantation of MACI.

Local treatment guidelines regarding the use of thromboprophylaxis and antibiotic prophylaxis around orthopaedic surgery should be followed. Use in patients with local inflammations or active infections in the bone, joint, and surrounding soft tissue should be temporarily deferred until documented recovery.

The MACI implant is not recommended during pregnancy. For implantations post-pregnancy, the safety of breast feeding to infant has not been determined.

Use of MACI in pediatric patients (younger than 18 years of age) or patients over 65 years of age has not been established.

The most frequently occurring adverse reactions reported for MACI ($\geq 5\%$) were arthralgia, tendonitis, back pain, joint swelling, and joint effusion.

Serious adverse reactions reported for MACI were arthralgia, cartilage injury, meniscus injury, treatment failure, and osteoarthritis.

Please see [full Prescribing Information](#) or visit [MACI.com](#).



64 Sidney Street
Cambridge, MA 02139
800-453-6948
www.MACI.com

MACI[®] is a registered trademark of Vericel Corporation.
©2020 Vericel Corporation. All rights reserved. PP.US.MAC.1129 v1.0

MACI.COM

Use of MACI (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) in the United States

Preliminary Experience

James L. Carey,^{*†} MD, MPH, Ann E. Remmers,[‡] PhD, and David C. Flanigan,[§] MD

Investigation performed at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Background: In December 2016, MACI (autologous cultured chondrocytes on porcine collagen membrane) received approval from the US Food and Drug Administration for the treatment of symptomatic articular cartilage defects of the knee with or without bone involvement in adults.

Purpose: To describe the cartilage defects and patient characteristics for 1000 adult patients treated with MACI for knee cartilage repair in the United States.

Study Design: Case series; Level of evidence, 4.

Methods: Data collected by Vericel for adult patients treated for articular cartilage defects of the knee were reconciled and summarized. Data were collected for 1000 consecutive patients starting on July 1, 2017, when Carticel (the prior generation of autologous cultured chondrocytes) was no longer available. Patient names were removed for confidentiality, and patients were identified by MACI lot number and surgery date. Safety data were derived from the pharmacovigilance database. Patient demographics, cartilage defect characteristics, concomitant surgical procedures, and adverse events were summarized with descriptive statistics.

Results: A total of 1000 adults and 1010 knee joints were implanted with MACI by 372 surgeons. The male (49.6%)-to-female (50.4%) ratio was evenly split, and the mean age was 34.0 years. The majority of patients (68.1%) had a single cartilage defect treated, and the mean treated defect size was 4.7 cm². The mean total treated lesion size, including multiple defects, was 5.8 cm². The patella was the most commonly treated joint surface (32.7%), followed by the medial femoral condyle (31.3%). Most patients (92.4%) had concomitant surgical procedures at the time of cartilage biopsy acquisition. The most common concomitant procedures at the time of biopsy procurement included cartilage debridement (83.7%) and meniscal resection (11.3%). The most common planned concomitant surgeries at the time of MACI implantation were anterior tibial tubercleplasty (7.8%) and reconstruction of dislocating patella (5.5%). Few patients (2.6%) had adverse events.

Conclusion: Patient age and mean total MACI-treated defect size in the United States are similar to the findings of the pivotal European SUMMIT (Superiority of MACI Implant Versus Microfracture Treatment) trial and other studies from outside the United States. Treatment of multiple cartilage defects is more frequent in the United States than elsewhere.

Keywords: autologous chondrocyte implantation; MACI; cartilage repair

Full-thickness articular cartilage defects of the knee do not heal spontaneously. They may cause pain and symptoms such as swelling, catching, and loss of knee function. Several cost-effective treatments for symptomatic cartilage defects are available,³ including autologous cultured chondrocytes on porcine collagen membrane (MACI; Vericel Corporation).

In December 2016, MACI received approval from the US Food and Drug Administration (FDA) for the treatment of symptomatic articular cartilage defects of the knee with or without bone involvement in adults. No patients had been treated with this autologous cellularized scaffold product in the United States prior to this FDA approval. Of note, however, is that other types of matrix-associated chondrocytes have been in clinical development in the United States, and the prior generation of FDA-approved autologous cultured chondrocytes (Carticel; Vericel Corporation) had been used in conjunction with collagen

The Orthopaedic Journal of Sports Medicine, 8(8), 2325967120941816

DOI: 10.1177/2325967120941816

© The Author(s) 2020

This open-access article is published and distributed under the Creative Commons Attribution - NonCommercial - No Derivatives License (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits the noncommercial use, distribution, and reproduction of the article in any medium, provided the original author and source are credited. You may not alter, transform, or build upon this article without the permission of the Author(s). For article reuse guidelines, please visit SAGE's website at <http://www.sagepub.com/journals-permissions>.

membranes off-label. The FDA approval of MACI was supported by the results of the European SUMMIT (Superiority of MACI Implant Versus Microfracture Treatment) trial—a phase 3, two-year, prospective, multicenter, randomized, open-label, parallel-group study that enrolled a total of 144 patients who had at least 1 symptomatic Outerbridge grade III or IV focal cartilage defect on the medial femoral condyle, lateral femoral condyle, and/or trochlea.⁷

MACI-treated study participants had a mean age of 34.8 years, and 63% were male. The majority of patients (82%) had single cartilage defects. The mean cartilage defect size was 4.9 cm², and 75% of the treated defects were located on the medial femoral condyle. The treatment of symptomatic cartilage knee defects by MACI was better than treatment with microfracture, in terms of both clinical results and statistical significance.⁷ All patients from the 2-year study had the option to enroll in a 3-year follow-up study (extension study), in which 128 patients participated. At 5 years after treatment, the improvement seen in MACI over microfracture with regard to the co-primary endpoint of the Knee injury and Osteoarthritis Outcome Score for pain and function was maintained and was clinically and statistically significant.¹

All clinical experience with this autologous cellularized scaffold product had been outside the United States until the first implant of MACI in the United States in January 2017. A literature report summarizing data from 2690 patients with planned MACI treatment from 9 European countries, Australia, and Singapore reported that the mean patient age was 33.7 years and 67% of patients were male. The majority of patients (81%) had single cartilage defects. The mean cartilage defect size was 5.6 cm² in that report.⁴ To evaluate whether clinical use of MACI in the United States differed from that in Europe or differed from that in clinical trial experience, the purpose of the current study was to summarize the patient demographics, cartilage lesion characteristics, concomitant surgical procedures, and adverse events for 1000 US MACI-treated patients after the discontinuation of Carticel (first-generation autologous chondrocyte implantation product).

METHODS

Data were collected for 1000 consecutive patients starting on July 1, 2017, when Carticel (first-generation autologous chondrocyte implantation product) was no longer available. Patient names were removed for confidentiality,

and patients were identified by MACI lot number and surgery date. Adverse events, collected as part of the FDA's mandatory safety reporting requirements for licensed products, were derived from the pharmacovigilance database for these 1000 patients from July 1, 2017, to November 30, 2019.

MACI Manufacturing

Vericel provided a cartilage biopsy kit for acquisition of cartilage. All cartilage specimens sent to Vericel were accessioned; chondrocytes were cultured and cryopreserved until a MACI order was received. Information recorded on the biopsy transmittal notice was entered in a customer relationship management (CRM) database. Each biopsy was assigned a unique lot number. Upon MACI order receipt, MACI was manufactured and release-tested before shipment for surgery. Information from the MACI order form was entered into a CRM database.

MACI Treatment

All surgeons implanting MACI had undergone training in cartilage biopsy procurement, MACI implantation, and post-MACI rehabilitation before shipment of MACI. The cartilage defects were to be prepared and the MACI implanted as described in the MACI prescribing information. Vericel cell therapy specialists or their designees were generally present for MACI surgeries.

MACI Customer Relationship Management Databases

Adult patient demographics, concomitant biopsy procedures, and knee cartilage lesion characteristics (location, dimensions, bone involvement) were collected from the biopsy transmittal memo included with each cartilage biopsy. Patients with joints other than the knee implanted with MACI or pediatric patients (<17 years of age) were not included in this summary. Cartilage lesion information from the MACI order form and biopsy transmittal notice entered into CRM databases was merged, and potential discrepancies were resolved. Concomitant procedures planned at the time of MACI implantation in the CRM database were summarized based on Current Procedural Terminology codes.

*Address correspondence to James L. Carey, MD, MPH, Perelman School of Medicine, University of Pennsylvania, Penn Sports Medicine Center, Weightman Hall, 1st floor, 235 South 33rd Street, Philadelphia, PA 19104, USA (email: james.carey@penmedicine.upenn.edu) (Twitter: @jamesleecarey1).

[†]University of Pennsylvania, Philadelphia, Pennsylvania, USA.

[‡]Vericel Corporation, Cambridge, Massachusetts, USA.

[§]The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Final revision submitted February 28, 2020; accepted March 12, 2020.

One or more of the authors has declared the following potential conflict of interest or source of funding: J.L.C. has received honoraria and speaking fees from Vericel and hospitality payments from Anika Therapeutics. A.E.R. is an employee of Vericel and has stock/stock options in Vericel. D.C.F. has received research support from Zimmer Biomet; consulting fees from CDC Medical, Ceterix, DePuy/Medical Device Business Services, Linvatec, Smith & Nephew, and Zimmer Biomet; nonconsulting fees from Vericel; and honoraria from Vericel. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.

Ethical approval for this study was obtained from The Ohio State University Biomedical Sciences Institutional Review Board (study No. 2019H0313).

Safety Data

Adverse events were coded using the Medical Dictionary for Regulatory Activities.

Data Analysis

Patient demographics, cartilage defect characteristics, concomitant surgical procedures, and adverse events were summarized with descriptive statistics through use of SAS (Version 9.4; SAS Institute). Figures were prepared by use of GraphPad Prism.

RESULTS

Patient Demographics

A total of 1000 adults and 1010 knee joints were treated with MACI by 372 surgeons (Table 1). The male (49.6%)-to-female (50.4%) ratio of treated adult patients was evenly split, and the mean \pm SD age was 34.0 ± 9.85 years (range, 17-61 years). The distribution of patient ages is shown in Figure 1; one-third of the treated patients were between 30 and 40 years of age. Of these 1000 patients, 10 had both knees treated with MACI. Further, 4 patients had both knees treated with MACI in 2 different surgeries, and 6 patients underwent MACI implantation in both knees on the same day.

Cartilage Defect Characteristics

The majority of patients had a single articular cartilage defect (68.1%); the mean treated single defect size was 4.7 cm^2 . The distribution of MACI-implanted cartilage defect sizes is shown in Figure 2; approximately two-thirds (65.4%) of the MACI-implanted defects were between 2 and 6 cm^2 . A total of 43 (4.3%) of the 1010 surgeries were for the treatment of cartilage defects with bone involvement. The mean total treated lesion size, including multiple cartilage defects, was 5.8 cm^2 . The patella was the most commonly implanted joint surface (32.7%), followed by the medial femoral condyle (31.3%). Mean cartilage defect sizes by location are shown in Figure 3.

The anatomic location of MACI-implanted defects for patients with 1 treated defect is summarized in Table 2. Defects were most commonly located in the patellofemoral joint in patients with 1 MACI-treated defect. Of the 326 patients with multiple MACI-implanted cartilage defects, the majority of patients (230/326; 70.6%) were treated in both the patellofemoral and tibiofemoral joints. A total of 73 of the 330 (22.1%) patients who received patellar treatment were treated with MACI on the patella and trochlea.

Concomitant Procedures

Almost all patients (92.4%) had concomitant surgical procedures at the time of cartilage biopsy acquisition (Table 3). The most common concomitant procedures at the time of

TABLE 1
Demographics and Cartilage Defect Characteristics

Patients, N ^a	1000
Age, y	
Mean \pm SD	34.0 \pm 9.85
Median	34
Minimum, maximum	17, 61
Sex, n (%)	
Female	504 (50.4)
Male	496 (49.6)
No. of surgeries, N1 ^b	1010
Joint to be treated, n (%)	
Right knee	468 (46.3)
Left knee	495 (49.0)
Bilateral knee on same day	6 (0.6)
Knee not specified	41 (4.1)
Primary defect ^c bony involvement, n (%)	43 (4.3)
No. of defects to be treated, n (%)	
1	688 (68.1)
2	261 (25.8)
3	55 (5.4)
4	6 (0.6)
Primary defect size, cm^2	
Mean \pm SD	4.68 \pm 2.8
Median	4.00
Minimum, maximum	0.6, 20.0
Total defect size, cm^2	
Mean \pm SD	5.79 \pm 4.3
Median	4.63
Minimum, maximum	0.6, 41.3

^aN is the number of patients in the analysis. Patients may undergo more than 1 surgery. Age and sex are counted and summarized based on the number of patients.

^bN1 is the number of surgeries. Joint to be treated, primary defect bony involvement, number of defects to be treated, primary defect size, and total defect size are counted and summarized based on the number of surgeries.

^cPrimary defect is defined as the larger/largest defect in the case of multiple defects.

biopsy procurement included debridement of the cartilage lesion (83.7%) and meniscal resection (11.3%).

Based on insurance preauthorization information in the CRM database, 132 patients (13.2%) had planned concomitant procedures at the time of MACI implantation (Table 4). The most common planned concomitant surgery was an anterior tibial tubercleplasty (7.8%), followed by reconstruction of dislocating patella (5.5%).

Safety

Very few patients (26; 2.6%) experienced adverse events (AEs). The most commonly reported AE was arthralgia, reported in 8 (0.8%) patients (Appendix Table A1). No events were reported in more than 1% of patients. A total of 85 AEs were reported in 26 patients with a follow-up period up to 28 months.

MACI treatment failure was reported in 3 patients. A 26-year-old man experienced knee swelling, pain, and graft delamination within 2 months of MACI implantation of a




Figure 1. Age distribution of patients treated with MACI (autologous cultured chondrocytes on porcine collagen membrane). Shown are the age categories for 1000 MACI-implanted adult patients age 17 years and older.




Figure 2. Size of cartilage defect treated with MACI (autologous cultured chondrocytes on porcine collagen membrane). Shown are the size categories for the larger/largest (if >1) MACI-implanted cartilage defect after debridement in 1010 MACI-implanted knees.

6-cm² defect on the right lateral femoral condyle; the patient underwent a concomitant meniscal transplant at the time of MACI implantation. The graft delamination was confirmed arthroscopically. Additional follow-up information was not provided. A 30-year-old woman treated with MACI for 1-cm² patellar and 0.25-cm² lateral femoral condyle defects experienced treatment failure 14 months after implantation. At the time of biopsy collection 9 months before MACI implantation, the patient was treated with microfracture/marrow stimulation. Additional follow-up




Figure 3. Cartilage defect size by defect location. Box and whisker plots of the mean (diamond), median (horizontal line through box), and 25th and 75th quartiles (lower and upper sides of each box) of the cartilage defect size (cm²) by defect location. The lower whisker defines the minimum observation, and the upper whisker defines the maximum defect sizes below the 1.5 interquartile range (IQR) of the 75th percentile. The open circles represent individual observations that are greater than 1.5 IQR above the 75th percentile. LFC, lateral femoral condyle; MFC, medial femoral condyle; Nobs, number of observations; Std, standard deviation.

TABLE 2
Defect Location in Surgeries Where a Single Defect Was Treated With MACI^a

Defect Location	No. (%) of Surgeries
Patella	251 (36.5)
Medial femoral condyle	200 (29.1)
Trochlea	122 (17.7)
Lateral femoral condyle	109 (15.8)
Tibia	6 (0.9)

^aPercentages are based on 688 surgeries that entailed a single defect. MACI, autologous cultured chondrocytes on porcine collagen membrane.

information was not provided. A 36-year-old woman treated with MACI for 3 left knee cartilage defects (total defect area, 10.5 cm²) of the left medial femoral condyle and trochlea experienced treatment failure on an unspecified date after MACI implantation. Prior knee surgeries included osteotomy, microfracture, and bone graft. Concomitant adverse events reported after MACI implantation and at the time of treatment failure included loneliness, depression, mental distress, and knee pain.

DISCUSSION

This study summarizes initial MACI use in the United States and indicates that patient age and articular cartilage defect size are comparable between populations in the

TABLE 3
Concomitant Surgeries at the Time of Cartilage Biopsy^a

	No. (%)
Patients who had concomitant surgical procedures	924 (92.4)
Concomitant surgical procedure	
Cartilage debridement/chondroplasty	837 (83.7)
Meniscal resection	113 (11.3)
Microfracture/marrow stimulation	50 (5.0)
Loose body removal	40 (4.0)
Anterior cruciate ligament reconstruction	28 (2.8)
Meniscal repair/reconstruction	27 (2.7)
Fixation of osteochondritis dissecans fragment	1 (0.1)
Other ^b	67 (6.7)

^aThe total sample was 1000 patients. Some patients had more than 1 procedure.

^bOther procedures in >1 patient include “not specified” (n = 51), lateral release (n = 3), osteochondral autograft (n = 3), and tibial tubercle osteotomy (n = 2).

TABLE 4
Concomitant Surgeries Planned at the Time of MACI Implantation^a

	No. (%)
Patients who had planned concomitant surgical procedures	132 (13.2)
Planned concomitant surgical procedure	
Anterior tibial tubercleplasty	78 (7.8)
Reconstruction of dislocating patella	55 (5.5)
Osteotomy, tibia (including high tibial osteotomy)	34 (3.4)
Ligamentous reconstruction	20 (2.0)
Lateral retinacular release	16 (1.6)
Osteotomy, femur	9 (0.9)
Osteochondral allograft	5 (0.5)
Implant removal (eg, screw)	4 (0.4)
Bone graft	2 (0.2)
Ligament repair	2 (0.2)
Meniscal transplant	1 (0.1)
Excision of lesion of meniscus or capsule	1 (0.1)
Excision or curettage of bone cyst or benign tumor of femur	1 (0.1)
Suture of infrapatellar tendon	1 (0.1)
Osteochondral autograft(s)	1 (0.1)
Injection(s), platelet-rich plasma	1 (0.1)

^aThe total sample was 1000 patients. MACI, autologous cultured chondrocytes on porcine collagen membrane. Some patients had more than 1 procedure.

United States and elsewhere⁴ as well as the pivotal European MACI SUMMIT study.⁷ The SUMMIT study required a minimum cartilage defect size of 3 cm²; a majority of US MACI use (77%) was in the treatment of cartilage defects 3 cm² or larger. For cartilage defects smaller than 2 cm², autologous chondrocyte implantation is not typically considered a primary treatment option²; however, a small percentage of patients (7%) had a primary cartilage defect smaller than 2 cm² treated with MACI. This pattern is consistent with use outside the United States, where approximately 7% of treated cartilage defects were 2 cm²

or smaller.⁴ Unlike a clinical trial, the current study did not collect patients' sports activity level, medical history, or prior surgeries; we speculate that these patients had failed prior more conservative treatment such as debridement or marrow stimulation.

Additionally, although the population sample sizes are quite different, the incidences of concomitant partial meniscectomy in the United States (11.3%) and the European SUMMIT study (11.1%) are similar. This is likely a result of clinical practice and clinical protocol (and therefore MACI prescribing information) recommending the need to address concomitant pathology in addition to MACI cartilage restoration. As would be expected, the rates of concomitant procedures were much higher (71%) in active US military servicemembers.⁹

In contrast to all previously reported MACI use, both male and female patients were treated in equal numbers in the United States, which may be a result of expanded access to recreational sports activities for girls and women in the United States as well as the high percentage of patellar cases. Use of autologous chondrocyte implantation for the treatment of patellar defects was more common in female than male patients in a multicenter US case series. A striking difference in MACI use within versus outside the United States is the higher percentage of patients (31% vs 19%) with more than 1 treated cartilage defect.⁴

These data represent our first opportunity to characterize MACI-treated patient and cartilage defect characteristics in the patella. (The summary by Foldager et al⁴ from patients outside the United States did not describe defect locations.) As expected, the mean size of the treated defect is smallest for the patella compared with other articular cartilage surfaces and also smaller than the mean defect size reported by Gomoll et al⁶ (5.4 cm²). Disease severity in that series⁶ was apparently greater than observed in the present cohort, as noted by a higher rate of bipolar lesions (27%) and concomitant osteotomy (69%).

Given the SUMMIT study's exclusion of malalignment requiring osteotomy to correct tibiofemoral or patellofemoral alignment, this real-world patient population requiring concomitant femoral or tibial osteotomy (n = 43 patients) provides the opportunity to study patient outcomes in this challenging patient population.⁵ Many literature reports (42% of clinical studies) describing cartilage restoration procedures excluded patients with malalignment, meniscal injury, and ligamentous instability.⁸

This early US experience saw no unexpected safety findings compared with the US prescribing information.

These data must be assessed within the context of the study limitations. This report would have been strengthened if it had included clinical outcomes including patient-reported outcome data. Given that the MACI treatments summarized in this report were conducted by more than 300 surgeons, outcomes data are being collected at only a subset of sites, especially patient-reported outcomes for patients treated with MACI in the patella. Unlike a clinical trial, the current study did not collect patients' sports activity level, medical history, or prior surgeries. Given that this information is derived from the database supporting insurance claims, there is the possibility of

underreporting of cartilage defect characteristics that may face challenges for insurance preapproval. Additionally, overestimation of a defect size may have taken place to facilitate insurance preapproval. There is the possibility of underreporting or overreporting of concomitant procedures, because this report summarized the percentage of patients with planned concomitant procedures (13.2%) rather than the actual concomitant procedures that were performed at the time of MACI implantation. In the current study, unlike a clinical study, the postmarketing AE data were spontaneously reported to the manufacturer and may not reflect rates observed in clinical studies or the real world. Also, the safety summary would benefit from a longer safety follow-up period than the posttreatment period of less than 2 years for some patients.

CONCLUSION

Patient age and mean total MACI-treated articular cartilage defect size in the United States are similar to that of the pivotal European SUMMIT clinical trial and real-world experience outside the United States. This initial experience with MACI suggests that treatment of multiple cartilage defects is more frequent in the United States than elsewhere. It remains to be seen whether the clinical outcomes after MACI treatment in the United States is comparable with those seen outside the United States or in the clinical trial setting.

ACKNOWLEDGMENT

The authors acknowledge Vericel Corporation Company employees Brad Rubin for providing the data sets, Hongbo

(Elaine) Li for data cleaning and clinical programming, and Fang Dong for clinical programming quality control.

REFERENCES

1. Brittberg M, Recker D, Ilgenfritz J, Saris DBF; SUMMIT Extension Study Group. Matrix-applied characterized autologous cultured chondrocytes versus microfracture five-year follow-up of a prospective randomized trial. *Am J Sports Med.* 2018;46(6):1343-1351.
2. Cole BJ, Pascual-Garrido C, Grumet RC. Surgical management of articular cartilage defects in the knee. *J Bone Joint Surg.* 2009;91:1778-1790.
3. Everhart JS, Campbell AB, Abouljoud MM, Kirven C, Flanigan DC. Cost-efficacy of knee cartilage defect treatments in the United States. *Am J Sports Med.* 2020;48(1):242-251.
4. Foldager CB, Farr J, Gomoll AH. Patients scheduled for chondrocyte implantation treatment with MACI have larger defects than those enrolled in clinical trials. *Cartilage.* 2016;7(2):140-148.
5. Gillogly S, Arnold RM. Autologous chondrocyte implantation and anteromedialization for isolated patellar articular cartilage lesions: 5- to 11-year follow-up. *Am J Sports Med.* 2014;42(4):912-920.
6. Gomoll AH, Gillogly SD, Cole BJ, et al. Autologous chondrocyte implantation in the patella: a multicenter experience. *Am J Sports Med.* 2014;42:1074-1081.
7. Saris D, Price A, Widuchowski W, et al. Matrix-applied characterized autologous cultured chondrocytes versus microfracture two-year follow-up of a prospective randomized trial. *Am J Sports Med.* 2014;42(6):1384-1394.
8. Sheppard WL, Hinckel BB, Arshi A, Sherman SL, Jones KJ. Accurate reporting of concomitant procedures is highly variable in studies investigating knee cartilage restoration [published online April 11, 2019]. *Cartilage.* doi:10.1177/1947603519841673
9. Zarkadis NJ, Belmont PJ, Zachilli MA, et al. Autologous chondrocyte implantation and tibial tubercle osteotomy for patellofemoral chondral defects: improved pain relief and occupational outcomes among US Army servicemembers. *Am J Sports Med.* 2018;46:3198-3208.

APPENDIX

TABLE A1
Adverse Events by MedDRA System Organ Class^a

MedDRA System Organ Class	Adverse Events, n (%)
Blood and lymphatic system disorders	1 (0.1)
Bone marrow edema	1 (0.1)
Gastrointestinal disorders	1 (0.1)
Abdominal pain, lower	1 (0.1)
General disorders and administration site conditions	15 (1.5)
Asthenia	1 (0.1)
Crepitations	1 (0.1)
Discomfort	1 (0.1)
Fatigue	1 (0.1)
Feeling abnormal	1 (0.1)
Gait inability	1 (0.1)
General physical health deterioration	1 (0.1)
Implant site pain	1 (0.1)
Inflammation	1 (0.1)

(continued)

TABLE A1 (continued)

MedDRA System Organ Class	Adverse Events, n (%)
Malaise	1 (0.1)
Pain	4 (0.4)
Peripheral swelling	1 (0.1)
Swelling	1 (0.1)
Treatment failure	3 (0.3)
Immune system disorders	1 (0.1)
Autoimmune disorder	1 (0.1)
Infections and infestations	2 (0.2)
Cellulitis	1 (0.1)
Folliculitis	1 (0.1)
Diverticulitis	1 (0.1)
Skin infection	1 (0.1)
Injury, poisoning, and procedural complications	11 (1.1)
Contusion	1 (0.1)
Graft complication	2 (0.2)
Graft delamination	4 (0.4)

(continued)

TABLE A1 (continued)

MedDRA System Organ Class	Adverse Events, n (%)
Graft overgrowth	3 (0.3)
Joint dislocation	1 (0.1)
Postprocedural swelling	1 (0.1)
Procedural pain	4 (0.4)
Investigations	1 (0.1)
White blood cell count increased	1 (0.1)
Musculoskeletal and connective tissue disorders	18 (1.3)
Arthralgia	8 (0.8)
Arthrofibrosis	1 (0.1)
Arthropathy	1 (0.1)
Cartilage hypertrophy	1 (0.1)
Chondromalacia	1 (0.1)
Joint effusion	3 (0.3)
Joint instability	1 (0.1)
Joint range of motion decreased	1 (0.1)
Joint stiffness	1 (0.1)
Joint swelling	3 (0.3)
Knee deformity	1 (0.1)
Muscle atrophy	2 (0.2)
Nervous system disorders	1 (0.1)
Sleep deficit	1 (0.1)

(continued)

TABLE A1 (continued)

MedDRA System Organ Class	Adverse Events, n (%)
Psychiatric disorders	4 (0.4)
Depression	1 (0.1)
Emotional distress	1 (0.1)
Frustration tolerance decreased	1 (0.1)
Insomnia	1 (0.1)
Psychiatric symptom	1 (0.1)
Stress	1 (0.1)
Respiratory, thoracic, and mediastinal disorders	1 (0.1)
Dyspnea	1 (0.1)
Pulmonary embolism	1 (0.1)
Skin and subcutaneous tissue disorders	1 (0.1)
Urticaria	1 (0.1)
Social circumstances	2 (0.2)
Immobilization prolonged	1 (0.1)
Loss of personal independence in daily activities	1 (0.1)
Vascular disorders	2 (0.2)
Deep vein thrombosis	2 (0.2)

^aNumber of patients with spontaneously reported adverse events = 26 out of 1000 (2.6%). Number of spontaneously reported adverse events = 85. MedDRA, Medical Dictionary for Regulatory Activities.